Please login to the form below

Not currently logged in
Email:
Password:

AZ and Sutter Health enter cardiometabolic collaboration

Three-year partnership will design and pilot new treatments

AstraZeneca AZ headquarters London UK 

AstraZeneca has joined forces with not-for-profit organisation Sutter Health on a research and innovation collaboration on cardiometabolic healthcare.

The three-year partnership will work to design, prototype and pilot innovative approaches to the form of healthcare, which focuses on the treatment and management of diseases such as diabetes, hypertension and high cholesterol in addition to more common complications such as heart attack, blindness or death.

Greg Keenan, VP medical affairs and US medical officer at AZ, commented: “Diabetes, high blood pressure and poorly controlled cholesterol can have an enormous impact on a person's quality of life and the cost of healthcare.

“We believe that Sutter Health and AZ will bring together unique expertise and experiences to improve the lives of patients. 

“Through this innovative research collaboration, we hope to improve the future of cardiometabolic care and translate solutions into programmes that health systems nationwide could implement.”

Researchers will aim to help speed up diagnosis and improve the quality of life of patients by creating technologies and treatments through a better understanding of existing gaps in cardiometabolic care.

The collaboration will focus on three key areas; utilising key data from across the Sutter Health network into a electronic system and conduct novel analytical steps to identify gaps; personalising care by designing, developing and implementing new tools to help patients and providers work together; and supporting the continuous knowledge growth of researchers.

Article by
Kirstie Pickering

11th May 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...